{"entity":{"id":"nct05435248","kind":"trial","name":"Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","aka":[],"tldr":"A phase 1/2 trial of HS-10375 in non-small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.","summary":"Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) is a phase 1/2 interventional study registered as NCT05435248 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 354 participants planned, started 2022-03-02 and due to reach its primary completion in 2025-03-31. Interventions recorded: HS-10375.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05435248","url":"https://clinicaltrials.gov/study/NCT05435248"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hansoh-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05435248-j-transl-med-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05435248","phase":"1/2","setting":"A Phase 1/2, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10375 Monotherapy in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT05435248","source":"https://clinicaltrials.gov/study/NCT05435248","fetchedAt":"2026-10-07T16:53:42.604Z","studySha256":"fe4f802e3cca89d1309aac40c2678fbfe3908819f4b07b75666dd52665943ef9","overallStatus":"RECRUITING","lastUpdatePosted":"2024-11-04","leadSponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":354,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2022-03-02","startedType":"actual","enrolled":354,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05435248/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/"}],"paper":[{"id":"paper-nct05435248-j-transl-med-2025","kind":"paper","name":"HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer","route":"/key-papers/paper-nct05435248-j-transl-med-2025/"}]}}